Similar Items: Successful and Risk-Minimizing Treatment of Ulcerative Colitis by Positive Switch from JAK Inhibitors to Ustekinumab
- Beta-Glucan modulates monocyte plasticity and differentiation capacity to mitigate DSS-induced colitis
- A non-canonical JAK/STAT pathway promotes viral replication through the lipoprotein receptor-related protein in ticks
- Biomarkers to predict outcomes in diabetic foot ulcers
- The predictive, preventive, and personalised medicine of thyroid eye disease: a comprehensive guide to risk minimization
- Real-Life Use of Subcutaneous Biologicals and JAK Inhibitors in IBD Maintenance Therapy: Treatment Continuation, Switching Patterns, and Concomitant Medications
- Recurrent local and systemic hypersensitivity reactions after switching back from subcutaneous to intravenous vedolizumab in ulcerative colitis: a case presentation